{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T04:44:35Z","timestamp":1766551475289,"version":"build-2065373602"},"reference-count":28,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Federal State of Tyrol","award":["LSD-A-6\/2\/107-2021","ZI. FIN-1\/103\/1189-2021","LSD-A-6\/2\/131-2021","LSD-A-6\/2\/145-2022"],"award-info":[{"award-number":["LSD-A-6\/2\/107-2021","ZI. FIN-1\/103\/1189-2021","LSD-A-6\/2\/131-2021","LSD-A-6\/2\/145-2022"]}]},{"name":"Tirol Kliniken GmbH","award":["LSD-A-6\/2\/107-2021","ZI. FIN-1\/103\/1189-2021","LSD-A-6\/2\/131-2021","LSD-A-6\/2\/145-2022"],"award-info":[{"award-number":["LSD-A-6\/2\/107-2021","ZI. FIN-1\/103\/1189-2021","LSD-A-6\/2\/131-2021","LSD-A-6\/2\/145-2022"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: To provide updated estimates on SARS-CoV-2 antibody seroprevalence and average antibody titres for Central Europe. Methods: In repeat cross-sectional investigations (1 May 2022 to 9 March 2023) involving 28,768 blood donors in the Federal State of Tyrol, Austria (participation rate: 87.0%), we measured Spike receptor-binding domain (RBD) and Nucleocapsid IgG antibodies (37,065 and 12,645 samples), and estimated monthly seroprevalences and geometric mean titres. Results: Median age of participants was 45.4 years (range 18\u201370); 43.2% were female. Spike RBD IgG antibody seroprevalence was 96.3% (95% CI: 95.6\u201396.9%) in May 2022, 97.4% (96.7\u201398.0%) in December 2022, and 97.9% (96.4\u201398.8%) in March 2023. Among seropositive participants, geometric mean titres increased from 1400 BAU\/mL (95% CI: 1333\u20131471) in May 2022 to 1821 BAU\/mL (1717\u20131932) in December 2022, and dropped to 1559 BAU\/mL (1405\u20131729) by March 2023. Furthermore, titres differed markedly by vaccination status and history of infection, with being the highest in participants with booster vaccination and prior infection. In autumn 2022, Nucleocapsid IgG antibody seroprevalence ranged from 36.5% (35.0\u201338.1) in September to 39.2% (37.2\u201341.2) in December 2022. Conclusion: Seroprevalence of SARS-CoV-2 antibodies in blood donors from Tyrol, Austria, was remarkably stable from May 2022 to March 2023. In contrast, average Spike RBD IgG antibody titres peaked in December 2022.<\/jats:p>","DOI":"10.3390\/vaccines12030284","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T03:52:11Z","timestamp":1709869931000},"page":"284","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Anti-SARS-CoV-2 IgG Seroprevalence in Tyrol, Austria, among 28,768 Blood Donors between May 2022 and March 2023"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7860-7144","authenticated-orcid":false,"given":"Anita","family":"Siller","sequence":"first","affiliation":[{"name":"Central Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0260-3262","authenticated-orcid":false,"given":"Lisa","family":"Seekircher","sequence":"additional","affiliation":[{"name":"Institute of Health Economics, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Astl","sequence":"additional","affiliation":[{"name":"Central Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7988-853X","authenticated-orcid":false,"given":"Lena","family":"Tschiderer","sequence":"additional","affiliation":[{"name":"Institute of Health Economics, Medical University of Innsbruck, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregor A.","family":"Wachter","sequence":"additional","affiliation":[{"name":"Central Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Penz","sequence":"additional","affiliation":[{"name":"Central Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, 6020 Innsbruck, Austria"},{"name":"Division for Digital Health and Telemedicine, UMIT-Tirol, 6060 Hall in Tirol, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Huber","sequence":"additional","affiliation":[{"name":"Tyrolean Federal Institute for Integrated Care, Tirol Kliniken GmbH, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Gaber","sequence":"additional","affiliation":[{"name":"Blood Donor Service Tyrol of the Austrian Red Cross, 6063 Rum, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Schennach","sequence":"additional","affiliation":[{"name":"Central Institute for Blood Transfusion and Immunology, University Hospital Innsbruck, Tirol Kliniken GmbH, 6020 Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1866-7159","authenticated-orcid":false,"given":"Peter","family":"Willeit","sequence":"additional","affiliation":[{"name":"Institute of Health Economics, Medical University of Innsbruck, 6020 Innsbruck, Austria"},{"name":"Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, 1090 Vienna, Austria"},{"name":"Department of Public Health and Primary Care, University of Cambridge, Cambridge CB2 0BB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bergeri, I., Whelan, M.G., Ware, H., Subissi, L., Nardone, A., Lewis, H.C., Li, Z., Ma, X., Valenciano, M., and Cheng, B. (2022). Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med., 19.","DOI":"10.1371\/journal.pmed.1004107"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1016\/S2666-5247(23)00107-6","article-title":"Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: An open-label, observational phase 4 trial","volume":"4","author":"Seekircher","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Siller, A., Seekircher, L., Wachter, G.A., Astl, M., Tschiderer, L., Pfeifer, B., Gaber, M., Schennach, H., and Willeit, P. (2022). Seroprevalence, Waning and Correlates of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Large-Scale Study of 35,193 Blood Donors Conducted between June 2020 and September 2021. Viruses, 14.","DOI":"10.3390\/v14030568"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Seekircher, L., Siller, A., Astl, M., Tschiderer, L., Wachter, G.A., Pfeifer, B., Huber, A., Gaber, M., Schennach, H., and Willeit, P. (2022). Seroprevalence of Anti-SARS-CoV-2 IgG Antibodies in Tyrol, Austria: Updated Analysis Involving 22,607 Blood Donors Covering the Period October 2021 to April 2022. Viruses, 14.","DOI":"10.1101\/2022.07.28.22278141"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Karl, T., Schuster, A., Stangassinger, L.M., Stiboller, T., Cadamuro, J., and Oostingh, G.J. (2023). Factors Affecting SARS-CoV-2 IgG Production after Vaccination and\/or Disease: A Large-Scale Seroprevalence Study. Vaccines, 11.","DOI":"10.3390\/vaccines11101615"},{"key":"ref_6","unstructured":"\u00d6sterreichische Agentur f\u00fcr Gesundheit und Ern\u00e4hrungssicherheit GmbH (2022, September 17). Gesundheit f\u00fcr Mensch, Tier & Pflanze: Coronavirus. Available online: https:\/\/www.ages.at\/mensch\/krankheit\/krankheitserreger-von-a-bis-z\/coronavirus."},{"key":"ref_7","unstructured":"Abbott (2024, February 29). SARS-CoV-2 Immunoassays. Available online: https:\/\/www.corelaboratory.abbott\/int\/en\/offerings\/segments\/infectious-disease\/sars-cov-2.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval Estimation for a Binomial Proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Borena, W., B\u00e1nki, Z., Bates, K., Winner, H., Riepler, L., R\u00f6ssler, A., Pipperger, L., Theurl, I., Falkensammer, B., and Ulmer, H. (2021). Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl. EBioMedicine, 70.","DOI":"10.1016\/j.ebiom.2021.103534"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10158","DOI":"10.1038\/s41598-021-89711-5","article-title":"Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown","volume":"11","author":"Breyer","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Harthaller, T., Borena, W., Bante, D., Sch\u00e4fer, H., Strallhofer, O., Z\u00f6ggeler, T., Hochmuth, E., Hoch, L., R\u00f6ssler, A., and von Laer, D. (2022). High Prevalence of Undocumented SARS-CoV-2 Infections in the Pediatric Population of the Tyrolean District of Schwaz. Viruses, 14.","DOI":"10.3390\/v14102294"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00112-022-01491-y","article-title":"SARS-CoV-2-Seropr\u00e4valenz in \u00d6sterreich. Die Situation vor der Omikronwelle","volume":"170","author":"Kerbl","year":"2022","journal-title":"Monatsschrift Kinderheilkd."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"632942","DOI":"10.3389\/fmed.2021.632942","article-title":"SARS-CoV-2-Specific Antibody Prevalence and Symptoms in a Local Austrian Population","volume":"8","author":"Ladage","year":"2021","journal-title":"Front. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Nunhofer, V., Weidner, L., Hoeggerl, A.D., Zimmermann, G., Badstuber, N., Grabmer, C., Jungbauer, C., Lindlbauer, N., Held, N., and Pascariuc, M. (2022). Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection. Viruses, 14.","DOI":"10.3390\/v14030637"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rebholz, H., Braun, R.J., Saha, T., Harzer, O., Schneider, M., and Ladage, D. (2022). Longitudinal monitoring of SARS-CoV-2 spike protein-specific antibody responses in Lower Austria. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271382"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/pai.13459","article-title":"Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: A cross-sectional study","volume":"32","author":"Schmidthaler","year":"2021","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"989337","DOI":"10.3389\/fpubh.2022.989337","article-title":"Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak","volume":"10","author":"Willeit","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.cell.2022.03.019","article-title":"Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants","volume":"185","author":"Servellita","year":"2022","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shang, W., Kang, L., Cao, G., Wang, Y., Gao, P., Liu, J., and Liu, M. (2022). Percentage of Asymptomatic Infections among SARS-CoV-2 Omicron Variant-Positive Individuals: A Systematic Review and Meta-Analysis. Vaccines, 10.","DOI":"10.3390\/vaccines10071049"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1002\/jmv.28066","article-title":"Proportion of asymptomatic infection and nonsevere disease caused by SARS-CoV-2 Omicron variant: A systematic review and analysis","volume":"94","author":"Yu","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2222849","DOI":"10.1080\/22221751.2023.2222849","article-title":"Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020\u20132022","volume":"12","author":"Solastie","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100547","DOI":"10.1016\/j.lanepe.2022.100547","article-title":"Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: A population-based study","volume":"24","author":"Zaballa","year":"2022","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"104765","DOI":"10.1016\/j.jcv.2021.104765","article-title":"Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection","volume":"136","author":"Oyaert","year":"2021","journal-title":"J. Clin. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e146316","DOI":"10.1172\/jci.insight.146316","article-title":"A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2","volume":"6","author":"Majdoubi","year":"2021","journal-title":"JCI Insight"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Asamoah-Boaheng, M., Grunau, B., Haig, S., Karim, M.E., Kirkham, T., Lavoie, P.M., Sediqi, S., Drews, S.J., O\u2019Brien, S.F., and Barakauskas, V. (2023). Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: Implications for booster vaccination. Access Microbiol., 5.","DOI":"10.1099\/acmi.0.000678.v3"},{"key":"ref_26","first-page":"105","article-title":"Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study","volume":"78","author":"Lacey","year":"2023","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"The Lancet Infectious Diseases (2022). Why hybrid immunity is so triggering. Lancet Infect. Dis., 22, 1649.","DOI":"10.1016\/S1473-3099(22)00746-0"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/284\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:50Z","timestamp":1760105450000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["vaccines12030284"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12030284","relation":{},"ISSN":["2076-393X"],"issn-type":[{"type":"electronic","value":"2076-393X"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}